Agios to Present New Data on Mitapivat and Tebapivat in Rare Blood Disorders at 66th ASH Annual Meeting and Exposition
05 nov. 2024 09h05 HE
|
Agios Pharmaceuticals, Inc.
Agios announced new data on mitapivat and tebapivat (AG-946) will be featured in oral and poster presentations during the ASH Annual Meeting.
Agios Reports Business Highlights and Third Quarter 2024 Financial Results
31 oct. 2024 06h30 HE
|
Agios Pharmaceuticals, Inc.
Agios reports business highlights and financial results for the third quarter, ended September 30, 2024.
Agios Completes Enrollment of Phase 3 RISE UP Study of Mitapivat in Sickle Cell Disease
23 oct. 2024 07h00 HE
|
Agios Pharmaceuticals, Inc.
Agios today announced that enrollment is complete for the Phase 3 RISE UP study in sickle cell disease patients.
Agios to Webcast Conference Call of Third Quarter 2024 Financial Results on October 31, 2024
17 oct. 2024 07h00 HE
|
Agios Pharmaceuticals, Inc.
CAMBRIDGE, Mass., Oct. 17, 2024 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in cellular metabolism and PK activation pioneering therapies for rare diseases, today...
Agios Announces FDA Orphan Drug Designation Granted to Tebapivat (AG-946) for Treatment of Myelodysplastic Syndromes (MDS)
11 sept. 2024 07h00 HE
|
Agios Pharmaceuticals, Inc.
Agios today announced that the FDA has granted orphan drug designation to tebapivat (AG-946) for the treatment of myelodysplastic syndromes (MDS).
Agios to Present at the 2024 Cantor Global Healthcare Conference on September 18, 2024
05 sept. 2024 07h00 HE
|
Agios Pharmaceuticals, Inc.
Agios is scheduled to present at the 2024 Cantor Global Healthcare Conference on Wednesday, September 18, 2024, at 10:20 a.m. ET.
Agios to Receive $1.1 Billion in Milestone Payments Following FDA Approval of Vorasidenib
06 août 2024 17h50 HE
|
Agios Pharmaceuticals, Inc.
Agios will receive a total of $1.1 billion in milestone payments following the FDA approval of vorasidenib
Agios Reports Business Highlights and Second Quarter 2024 Financial Results
01 août 2024 06h31 HE
|
Agios Pharmaceuticals, Inc.
– Reported Positive Topline Data from Phase 3 ENERGIZE-T Study; Expect to File sNDA Based on ENERGIZE and ENERGIZE-T Studies Encompassing All Thalassemia Subtypes by End of 2024 – – Announced $905...
Agios Announces Results from Phase 3 ACTIVATE-KidsT Study of Mitapivat in Children with PK Deficiency Who Are Regularly Transfused
01 août 2024 06h30 HE
|
Agios Pharmaceuticals, Inc.
– ACTIVATE-KidsT is Agios’ First Pediatric Data Readout;Safety Results Consistent with Safety Profile for Mitapivat Previously Observed in Adultswith PK Deficiency Who are Regularly Transfused – –...
Agios to Webcast Conference Call of Second Quarter 2024 Financial Results on August 1, 2024
18 juil. 2024 07h00 HE
|
Agios Pharmaceuticals, Inc.
CAMBRIDGE, Mass., July 18, 2024 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in cellular metabolism and PK activation pioneering therapies for rare diseases, today...